Recruiting
Phase 2
Phase 3

NA-831, Atazanavir and Dexamethasone Combination Therapy for the Treatment of COVID-19 Infection

Sponsor:

Biomed Industries, Inc.

Code:

NCT04452565

Conditions

Coronavirus Infection

Severe Acute Respiratory Infection

Severe Acute Respiratory Syndrome Coronavirus 2

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Drug: NA-831

NA-831 and Atazanavir

NA-831and Dexamethasone

Atazanavir and Dexamethasone

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information